推荐产品
品質等級
化驗
≥98% (HPLC)
形狀
solid
顏色
white
溶解度
DMSO: >5 mg/mL at 60 °C
H2O: insoluble
起源
Boehringer Ingelheim
SMILES 字串
CCCc1nc2c(C)cc(cc2n1Cc3ccc(cc3)-c4ccccc4C(O)=O)-c5nc6ccccc6n5C
InChI
1S/C33H30N4O2/c1-4-9-30-35-31-21(2)18-24(32-34-27-12-7-8-13-28(27)36(32)3)19-29(31)37(30)20-22-14-16-23(17-15-22)25-10-5-6-11-26(25)33(38)39/h5-8,10-19H,4,9,20H2,1-3H3,(H,38,39)
InChI 密鑰
RMMXLENWKUUMAY-UHFFFAOYSA-N
基因資訊
human ... AGTR1(185)
正在寻找类似产品? 访问 产品对比指南
應用
替米沙坦已作为 AT1 受体拮抗剂用于研究其对心肌梗死小鼠模型的影响。本研究报道替米沙坦可抑制 CCN1 上调，降低 CCN2 水平心房心肌细胞 。替米沙坦也被用于评价其对心肌梗死小鼠肾皮质 CCN1 表达的影响 。此外，已在结直肠癌小鼠模型中测试替米沙坦检测其抑制肿瘤生长的疗效 。
生化／生理作用
替米沙坦是一种非肽类 1 血管紧张素受体拮抗剂。
特點和優勢
该化合物由 Boehringer Ingelheim 开发。要浏览其他制药公司开发的化合物列表批准的药物/候选药物的列表， 点击这里 。
这种化合物是 ADME 毒性研究的特色产品。点击此处发现更多特色 ADME 毒性产品。在sigma.com/discover-bsm可了解更多关于生物活性小分子的其他研究领域。
準備報告
替米沙坦可溶于 DMSO，浓度大于 5 mg/mL。不溶于水。
儲存類別代碼
11 - Combustible Solids
水污染物質分類（WGK）
WGK 3
閃點（°F）
Not applicable
閃點（°C）
Not applicable
個人防護裝備
Eyeshields, Gloves, type N95 (US)
其他客户在看
Marc P Maillard et al.
The Journal of pharmacology and experimental therapeutics, 302(3), 1089-1095 (2002-08-17)
In vitro studies have shown that telmisartan is an insurmountable angiotensin II subtype-1 (AT1) receptor antagonist. Herein, the molecular basis of this insurmountable antagonism has been investigated in vitro, and the effect of telmisartan has been compared in vivo with
Tomasz Andrzej Bonda et al.
Folia histochemica et cytobiologica, 51(1), 84-91 (2013-05-22)
Chronic heart failure often leads to worsening of the renal function. Mediators of this process include inflammatory and neuroendocrine factors. CCN1 (Cyr 61), a member of growth factor-inducible immediate early genes, which modulates inflammation and fibrogenesis, is excreted with urine
M Sharpe et al.
Drugs, 61(10), 1501-1529 (2001-09-18)
Telmisartan is an angiotensin II receptor antagonist that is highly selective for type 1 angiotensin II receptors. It was significantly more effective than placebo in large (n >100), double-blind, randomised, multicentre clinical trials in patients with mild to moderate hypertension.
Tomasz A Bonda et al.
Folia histochemica et cytobiologica, 50(1), 99-103 (2012-04-26)
Previous studies have reported the upregulation of CCN proteins early after acute heart injury. The aim of the present work was to evaluate the expression of the CCN1 and CCN2 proteins and their regulation by angiotensin II in the atrial
Eleanor I Ager et al.
BMC cancer, 11, 274-274 (2011-06-28)
Targeting of the renin angiotensin system (RAS) reduces tumour growth in experimental models of cancer. We aimed to establish if combined targeting of the 'classical' and 'alternative' arms of the RAS could result in synergistic inhibition of colorectal cancer (CRC)
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门